Insider · CIK 0001783165

Adjuvant Global Health Technology Fund, L.P.

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001783165

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-01-16	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−84.1K sh	$19.65	−$1.65M	1,995,958
2024-01-16	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−15.9K sh	$19.65	−$313K	377,542
2023-11-14	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−1,522 sh	$16.15	−$24.6K	2,080,051
2023-11-14	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−288 sh	$16.15	−$4,650.048	393,449
2023-10-02	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−4,770 sh	$16.07	−$76.7K	2,081,573
2023-10-02	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−902 sh	$16.07	−$14.5K	393,737
2023-09-29	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−83.3K sh	$16.28	−$1.36M	2,086,343
2023-09-29	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−15.8K sh	$16.28	−$257K	394,639
2023-09-28	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−7,160 sh	$16.11	−$115K	2,169,680
2023-09-28	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−1,356 sh	$16.11	−$21.8K	410,403
2023-09-27	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−707 sh	$16.07	−$11.4K	2,176,840
2023-09-27	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−134 sh	$16.07	−$2,153.38	411,759
2023-09-13	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−336 sh	$16.00	−$5,376	2,177,547
2023-09-13	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−64 sh	$16.00	−$1,024	411,893
2023-09-07	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−2,841 sh	$16.05	−$45.6K	2,177,883
2023-09-07	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−537 sh	$16.05	−$8,618.85	411,957
2023-09-06	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−3,164 sh	$16.02	−$50.7K	2,180,724
2023-09-06	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−598 sh	$16.02	−$9,579.96	412,494
2023-08-23	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−336 sh	$16.00	−$5,376	2,183,888
2023-08-23	ANTXAN2 Therapeutics, Inc.S Sale	10% Owner	SSale	−64 sh	$16.00	−$1,024	413,092
2022-06-06	ANTXAN2 Therapeutics, Inc.J Other	10% Owner	JOther	−26.5K sh	$15.00	−$398K	2,184,224
2022-06-06	ANTXAN2 Therapeutics, Inc.J Other	10% Owner	JOther	+26.5K sh	$15.00	+$398K	413,156
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+1.65M sh	—	—	1,651,636
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+312K sh	—	—	312,415
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+392K sh	—	—	2,044,069
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+74.2K sh	—	—	386,645
2022-03-29	ANTXAN2 Therapeutics, Inc.P Purchase	10% Owner	PPurchase	+167K sh	$15.00	+$2.5M	2,210,735
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−1.65M sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−312K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−392K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−74.2K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+1.65M sh	—	—	1,651,636
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+312K sh	—	—	312,415
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+392K sh	—	—	2,044,069
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	10% Owner	CConversion	+74.2K sh	—	—	386,645
2022-03-29	ANTXAN2 Therapeutics, Inc.P Purchase	10% Owner	PPurchase	+167K sh	$15.00	+$2.5M	2,210,735
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−1.65M sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	10% Owner	CConversion	−312K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−392K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	10% Owner	CConversion	−74.2K sh	—	—	0

Recent filings

Accepted (ET)
Jan 184
Adjuvant Global Health Technology Fund, L.P.0000950170-24-005513
SEC(opens sec.gov)
Nov 164
Adjuvant Global Health Technology Fund, L.P.0000950170-23-064611
SEC(opens sec.gov)
Oct 34
Adjuvant Global Health Technology Fund, L.P.0000950170-23-051728
SEC(opens sec.gov)
Sep 294
Adjuvant Global Health Technology Fund, L.P.0000950170-23-050853
SEC(opens sec.gov)
Sep 154
Adjuvant Global Health Technology Fund, L.P.0000950170-23-048422
SEC(opens sec.gov)
Sep 84
Adjuvant Global Health Technology Fund, L.P.0000950170-23-047312
SEC(opens sec.gov)
Aug 254
Adjuvant Global Health Technology Fund, L.P.0000950170-23-044594
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.10% OwnerANTX

Address

C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404

NEW YORK, NY, 10017